Geneva Capital Management’s DexCom DXCM Stock Holding History

Geneva Capital Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.83M	Sell	131,083 -7,780	-6%	-$518K	0.2%	86
2026 Q1	$8.72M	Buy	138,863 +3,933	+3%	+$274K	0.19%	87
2025 Q4	$8.96M	Sell	134,930 -13,165	-9%	-$851K	0.17%	89
2025 Q3	$9.97M	Sell	148,095 -7,690	-5%	-$609K	0.17%	90
2025 Q2	$13.6M	Buy	155,785 +37,713	+32%	+$2.96M	0.23%	88
2025 Q1	$8.06M	Buy	118,072 +5,095	+5%	+$416K	0.15%	92
2024 Q4	$8.79M	Sell	112,977 -17,691	-14%	-$1.31M	0.15%	98
2024 Q3	$8.76M	Buy	130,668 +4,414	+3%	+$362K	0.15%	99
2024 Q2	$14.3M	Buy	+126,254	New	+$16M	0.26%	88

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geneva Capital Management's DXCM Position: Q2 2026 in Review

Geneva Capital Management reduced its DexCom (DXCM) stake by 5.6% in Q2 2026, selling an estimated $518K and leaving 131,083 shares worth $8.83M. The position accounts for 0.2% of the portfolio, ranked #86.

Geneva Capital Management first reported a position in DXCM in Q2 2024 and has held it in 9 quarters since. The position peaked at $14.3M in Q2 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

Geneva Capital Management held 131,083 shares of DexCom worth $8.83M as of Q2 2026.
Geneva Capital Management sold 7,780 DexCom shares in Q2 2026, an estimated $518K.
DexCom made up 0.2% of Geneva Capital Management's portfolio in Q2 2026, its #86 holding.
Geneva Capital Management first reported a position in DexCom in Q2 2024 and has held it in 9 quarters since.
Geneva Capital Management's DexCom position peaked at $14.3M in Q2 2024.
968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Geneva Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.